159 related articles for article (PubMed ID: 29555627)
1. Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.
Scheele S; Geiger JA; DeRocher AE; Choi R; Smith TR; Hulverson MA; Vidadala RSR; Barrett LK; Maly DJ; Merritt EA; Ojo KK; Van Voorhis WC; Parsons M
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555627
[TBL] [Abstract][Full Text] [Related]
2. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.
Johnson SM; Murphy RC; Geiger JA; DeRocher AE; Zhang Z; Ojo KK; Larson ET; Perera BG; Dale EJ; He P; Reid MC; Fox AM; Mueller NR; Merritt EA; Fan E; Parsons M; Van Voorhis WC; Maly DJ
J Med Chem; 2012 Mar; 55(5):2416-26. PubMed ID: 22320388
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.
Rutaganira FU; Barks J; Dhason MS; Wang Q; Lopez MS; Long S; Radke JB; Jones NG; Maddirala AR; Janetka JW; El Bakkouri M; Hui R; Shokat KM; Sibley LD
J Med Chem; 2017 Dec; 60(24):9976-9989. PubMed ID: 28933846
[TBL] [Abstract][Full Text] [Related]
4. Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection.
Doggett JS; Ojo KK; Fan E; Maly DJ; Van Voorhis WC
Antimicrob Agents Chemother; 2014 Jun; 58(6):3547-9. PubMed ID: 24687502
[TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum.
Winzer P; Müller J; Aguado-Martínez A; Rahman M; Balmer V; Manser V; Ortega-Mora LM; Ojo KK; Fan E; Maly DJ; Van Voorhis WC; Hemphill A
Antimicrob Agents Chemother; 2015 Oct; 59(10):6361-74. PubMed ID: 26248379
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy.
Ojo KK; Dangoudoubiyam S; Verma SK; Scheele S; DeRocher AE; Yeargan M; Choi R; Smith TR; Rivas KL; Hulverson MA; Barrett LK; Fan E; Maly DJ; Parsons M; Dubey JP; Howe DK; Van Voorhis WC
Int J Parasitol; 2016 Dec; 46(13-14):871-880. PubMed ID: 27729271
[TBL] [Abstract][Full Text] [Related]
7. Identifying the Target of an Antiparasitic Compound in
Herneisen AL; Sidik SM; Markus BM; Drewry DH; Zuercher WJ; Lourido S
ACS Chem Biol; 2020 Jul; 15(7):1801-1807. PubMed ID: 32597628
[TBL] [Abstract][Full Text] [Related]
8. Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with Toxoplasma gondii during Pregnancy.
Sánchez-Sánchez R; Ferre I; Re M; Ramos JJ; Regidor-Cerrillo J; Pizarro Díaz M; González-Huecas M; Tabanera E; Benavides J; Hemphill A; Hulverson MA; Barrett LK; Choi R; Whitman GR; Ojo KK; Van Voorhis WC; Ortega-Mora LM
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061151
[TBL] [Abstract][Full Text] [Related]
9. Use of the kinase inhibitor analog 1NM-PP1 reveals a role for Toxoplasma gondii CDPK1 in the invasion step.
Sugi T; Kato K; Kobayashi K; Watanabe S; Kurokawa H; Gong H; Pandey K; Takemae H; Akashi H
Eukaryot Cell; 2010 Apr; 9(4):667-70. PubMed ID: 20173034
[TBL] [Abstract][Full Text] [Related]
10. Anticoccidial kinase inhibitors: identification of protein kinase targets secondary to cGMP-dependent protein kinase.
Donald RG; Zhong T; Wiersma H; Nare B; Yao D; Lee A; Allocco J; Liberator PA
Mol Biochem Parasitol; 2006 Sep; 149(1):86-98. PubMed ID: 16765465
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.
Kuhlenschmidt TB; Rutaganira FU; Long S; Tang K; Shokat KM; Kuhlenschmidt MS; Sibley LD
Antimicrob Agents Chemother; 2016 Jan; 60(1):570-9. PubMed ID: 26552986
[TBL] [Abstract][Full Text] [Related]
12. Reduced Activity of Mutant Calcium-Dependent Protein Kinase 1 Is Compensated in Plasmodium falciparum through the Action of Protein Kinase G.
Bansal A; Ojo KK; Mu J; Maly DJ; Van Voorhis WC; Miller LH
mBio; 2016 Dec; 7(6):. PubMed ID: 27923926
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
Janetka JW; Hopper AT; Yang Z; Barks J; Dhason MS; Wang Q; Sibley LD
J Med Chem; 2020 Jun; 63(11):6144-6163. PubMed ID: 32420739
[TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice.
Anghel N; Winzer PA; Imhof D; Müller J; Langa X; Rieder J; Barrett LK; Vidadala RSR; Huang W; Choi R; Hulverson MA; Whitman GR; Arnold SL; Van Voorhis WC; Ojo KK; Maly DJ; Fan E; Hemphill A
Int J Antimicrob Agents; 2020 Sep; 56(3):106099. PubMed ID: 32707170
[TBL] [Abstract][Full Text] [Related]
15. A focused small-molecule screen identifies 14 compounds with distinct effects on Toxoplasma gondii.
Kamau ET; Srinivasan AR; Brown MJ; Fair MG; Caraher EJ; Boyle JP
Antimicrob Agents Chemother; 2012 Nov; 56(11):5581-90. PubMed ID: 22908155
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potential Toxoplasma gondii CDPK1 inhibitors with new scaffolds based on the combination of QSAR and scaffold-hopping method with in vitro validation.
Zhang P; Jia L; Tian Y; Xi L; Duan R; Chen X; Xiao J; Yao X; Lan J; Li S
Chem Biol Drug Des; 2020 May; 95(5):476-484. PubMed ID: 31436911
[TBL] [Abstract][Full Text] [Related]
17. The calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design.
Cardew EM; Verlinde CLMJ; Pohl E
Parasitology; 2018 Feb; 145(2):210-218. PubMed ID: 29191253
[TBL] [Abstract][Full Text] [Related]
18. Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis.
Lapinskas PJ; Ben-Harari RR
Postgrad Med; 2019 Nov; 131(8):589-596. PubMed ID: 31399001
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis.
Hulverson MA; Bruzual I; McConnell EV; Huang W; Vidadala RSR; Choi R; Arnold SLM; Whitman GR; McCloskey MC; Barrett LK; Rivas KL; Scheele S; DeRocher AE; Parsons M; Ojo KK; Maly DJ; Fan E; Van Voorhis WC; Doggett JS
J Infect Dis; 2019 Apr; 219(9):1464-1473. PubMed ID: 30423128
[TBL] [Abstract][Full Text] [Related]
20. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
Larson ET; Ojo KK; Murphy RC; Johnson SM; Zhang Z; Kim JE; Leibly DJ; Fox AM; Reid MC; Dale EJ; Perera BG; Kim J; Hewitt SN; Hol WG; Verlinde CL; Fan E; Van Voorhis WC; Maly DJ; Merritt EA
J Med Chem; 2012 Mar; 55(6):2803-10. PubMed ID: 22369268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
